Following the drug's release in the United States, the pharmaceutical business, federal authorities, and impacted communities engaged in previously unheard-of court fights. Lawsuits were brought against Purdue Pharma, the manufacturer of OxyContin, for deceptive advertising tactics that minimized the risk of addiction. These incidents exposed serious weaknesses in the nation's drug laws and enforcement protocols, which prompted changes to corporate responsibility, healthcare policy, and prescribing guidelines for opioids.